Unity Biotechnology Inc - Asset Resilience Ratio
Unity Biotechnology Inc (UBX) has an Asset Resilience Ratio of 29.44% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Unity Biotechnology Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Unity Biotechnology Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Unity Biotechnology Inc.
Liquid Assets Composition Over Time
This chart breaks down Unity Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Unity Biotechnology Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $8.93 Million | 29.44% |
| Total Liquid Assets | $8.93 Million | 29.44% |
Asset Resilience Insights
- Very High Liquidity: Unity Biotechnology Inc maintains exceptional liquid asset reserves at 29.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Unity Biotechnology Inc Industry Peers by Asset Resilience Ratio
Compare Unity Biotechnology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Unity Biotechnology Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Unity Biotechnology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 41.55% | $15.65 Million | $37.66 Million | +5.94pp |
| 2023-12-31 | 35.62% | $23.40 Million | $65.69 Million | -30.37pp |
| 2022-12-31 | 65.99% | $82.06 Million | $124.35 Million | +21.75pp |
| 2021-12-31 | 44.24% | $55.17 Million | $124.71 Million | -6.87pp |
| 2020-12-31 | 51.11% | $79.89 Million | $156.32 Million | -8.42pp |
| 2019-12-31 | 59.53% | $90.02 Million | $151.22 Million | -26.34pp |
| 2018-12-31 | 85.86% | $155.74 Million | $181.38 Million | +8.22pp |
| 2017-12-31 | 77.64% | $79.21 Million | $102.02 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $96.65 Million | -- |
About Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develop… Read more